$TRDA
Entrada Therapeutics, Inc. Stock $trda

$trda Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000168937524000027 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$94.69M	$59.12M
YoY Change	421.16%	134.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.236M	$9.399M
YoY Change	13.06%	18.41%
% of Gross Profit
Research & Development	$32.04M	$28.61M
YoY Change	21.81%	23.83%
% of Gross Profit
Depreciation & Amortization	$900.0K	$900.0K
YoY Change	23.29%	80.0%
% of Gross Profit
Operating Expenses	$41.27M	$38.01M
YoY Change	19.73%	22.45%
Operating Profit	$53.42M	$21.11M
YoY Change	-427.77%	-465.28%
Interest Expense	$4.366M	$4.214M
YoY Change	3.51%	58.6%
% of Operating Profit	8.17%	19.96%
Other Income/Expense, Net	$4.366M	$4.214M
YoY Change	3.51%	58.6%
Pretax Income	$57.79M	$25.33M
YoY Change	-578.35%	-910.98%
Income Tax	$2.800M	$1.800M
% Of Pretax Income	4.85%	7.11%
Net Earnings	$55.03M	$23.50M
YoY Change	-312.25%	-452.05%
Net Earnings / Revenue	58.11%	39.74%
Basic Earnings Per Share	$1.61	$0.70
Diluted Earnings Per Share	$1.55	$0.68
COMMON SHARES
Basic Shares Outstanding	33.76M shares	33.60M shares
Diluted Shares Outstanding	35.51M shares	34.79M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$469.7M	$327.4M
YoY Change	24.67%	-20.46%
Cash & Equivalents	$185.3M	$68.44M
Short-Term Investments	$284.5M	$259.0M
Other Short-Term Assets	$12.12M	$9.244M
YoY Change	25.4%	-42.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$489.5M	$414.2M
YoY Change	25.46%	-4.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.34M	$11.00M
YoY Change	-88.58%	17.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$747.0K	$2.762M
YoY Change	-83.36%	-80.05%
Total Long-Term Assets	$92.43M	$96.67M
YoY Change	-10.95%	133.32%
TOTAL ASSETS
Total Short-Term Assets	$489.5M	$414.2M
Total Long-Term Assets	$92.43M	$96.67M
Total Assets	$582.0M	$510.8M
YoY Change	17.81%	7.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.635M	$2.527M
YoY Change	-32.49%	-60.97%
Accrued Expenses	$11.00M	$8.792M
YoY Change	-24.22%	-24.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$85.81M	$173.9M
YoY Change	-31.87%	17.85%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$66.23M	$67.54M
YoY Change	-58.9%	-31.34%
Total Long-Term Liabilities	$66.23M	$67.54M
YoY Change	-58.9%	-31.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$85.81M	$173.9M
Total Long-Term Liabilities	$66.23M	$67.54M
Total Liabilities	$152.0M	$241.5M
YoY Change	-47.04%	-1.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.4M	-$171.5M
YoY Change	-47.31%	-12.05%
Common Stock	$4.000K	$3.000K
YoY Change	33.33%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$429.9M	$269.4M
YoY Change
Total Liabilities & Shareholders Equity	$582.0M	$510.8M
YoY Change	17.81%	7.42%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$55.03M	$23.50M
YoY Change	-312.25%	-452.05%
Depreciation, Depletion And Amortization	$900.0K	$900.0K
YoY Change	23.29%	80.0%
Cash From Operating Activities	$39.83M	-$25.52M
YoY Change	-213.51%	-112.55%
INVESTING ACTIVITIES
Capital Expenditures	$1.046M	$838.0K
YoY Change	-31.27%	-49.76%
Acquisitions
YoY Change
Other Investing Activities	-$23.34M	$26.99M
YoY Change	-79.11%	-169.59%
Cash From Investing Activities	-$24.38M	$26.15M
YoY Change	-78.47%	-164.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	101.4M	$206.0K
YoY Change	22781.94%	-98.95%
NET CHANGE
Cash From Operating Activities	39.83M	-$25.52M
Cash From Investing Activities	-24.38M	$26.15M
Cash From Financing Activities	101.4M	$206.0K
Net Change In Cash	116.8M	$834.0K
YoY Change	-178.98%	-99.54%
FREE CASH FLOW
Cash From Operating Activities	$39.83M	-$25.52M
Capital Expenditures	$1.046M	$838.0K
Free Cash Flow	$38.79M	-$26.36M
YoY Change	-205.94%	-113.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28608000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23102000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9399000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7938000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	38007000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	31040000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	21113000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5780000	usd
CY2024Q1	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	4214000	usd
CY2023Q1	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	2657000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4214000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2657000	usd
CY2024Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	25327000	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-3123000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1831000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3551000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	23496000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6674000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.68
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33497072	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32374299	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34790925	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32374299	shares
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-441000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1415000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-441000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1415000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	23055000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5259000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	212554000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	129000	usd
CY2023Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	26000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19407000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2755000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1415000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6674000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	229612000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	242360000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	206000	usd
CY2024Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	13000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3733000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-441000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	23496000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	269367000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	23496000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-6674000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	934000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	541000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3733000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2755000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2037000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	237000	usd
CY2024Q1	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	71636000	usd
CY2023Q1	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	6297000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2680000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4339000	usd
CY2024Q1	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-2532000	usd
CY2023Q1	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3332000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-28000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8633000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-655000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	534000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2522000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4107000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1831000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1798000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1950000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	17895000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	211582000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25519000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	203399000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	838000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1668000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	96935000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	101776000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	123920000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	63000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26147000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40444000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19407000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	206000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	129000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	206000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19536000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	834000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	182491000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71552000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49107000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72386000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231598000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	115000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000	usd
CY2024Q1	trda	Right Of Use Asset Surrendered As Part Of Lease Modification RightOfUseAssetSurrenderedAsPartOfLeaseModification	0	usd
CY2023Q1	trda	Right Of Use Asset Surrendered As Part Of Lease Modification RightOfUseAssetSurrenderedAsPartOfLeaseModification	7761000	usd
CY2024Q1	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	0	usd
CY2023Q1	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	617000	usd
CY2024Q1	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	13000	usd
CY2023Q1	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	26000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171500000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	327400000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68436000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67602000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72386000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71552000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	259224000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	36000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	282000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	258978000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	284172000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	265000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	70000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	284367000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	42	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	244200000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	1000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	1700000	usd
CY2024Q1	us-gaap	Cash Cash	500000	usd
CY2023Q4	us-gaap	Cash Cash	500000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17747000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17114000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6745000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5923000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11002000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11191000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	900000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	500000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3038000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6660000	usd
CY2024Q1	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	3716000	usd
CY2023Q4	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	2894000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1297000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	767000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	741000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1004000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8792000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11325000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10729447	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9220192	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3733000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2755000	usd
CY2024Q1	trda	Stock Issued During Period Shares Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions	11334	shares
CY2023	trda	Stock Issued During Period Shares Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions	14745	shares
CY2024Q1	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	100000	usd
CY2023Q4	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	100000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5414360	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.42
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	542700	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.73
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30888	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.68
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	195221	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.77
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5730951	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.65
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3453494	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.91
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1268461	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	13.83
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	928290	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.76
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	132458	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	11.92
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	58404	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	13.65
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2005889	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	13.93
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1800000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3600000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	23496000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6674000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33497072	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32374299	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1293853	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34790925	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32374299	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.68
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3912009	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6064062	shares
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001689375-24-000027-index-headers.html	Edgar Link	pending
0001689375-24-000027-index.html	Edgar Link	pending
0001689375-24-000027.txt	Edgar Link	pending
0001689375-24-000027-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trda-20240331.htm	Edgar Link	pending
trda-20240331.xsd	Edgar Link	pending
trda-20240331x10qex3111.htm	Edgar Link	pending
trda-20240331x10qex3121.htm	Edgar Link	pending
trda-20240331x10qex3211.htm	Edgar Link	pending
trda-20240331_def.xml	Edgar Link	unprocessable
trda-20240331_pre.xml	Edgar Link	unprocessable
trda-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
trda-20240331_lab.xml	Edgar Link	unprocessable
trda-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRDA
Entrada Therapeutics, Inc. Stock $trda

2024 Q2 Form 10-Q Financial Statement

#000168937524000027 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA Entrada Therapeutics, Inc. Stock $trda

2024 Q2 Form 10-Q Financial Statement

#000168937524000027 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA
Entrada Therapeutics, Inc. Stock $trda